PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PharmaTher Holdings Ltd. announced they have canceled a planned meeting with the FDA after receiving satisfactory preliminary responses regarding their Ketamine product’s application. The company is addressing minor deficiencies noted by the FDA and plans to resubmit necessary information by January 2025.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.